Invenra Inc. Announces a Strategic Collaboration with Catalent to Co-Discover Novel Bispecific ADCs

MADISON, Wis.--(BUSINESS WIRE)--Invenra Inc., an innovative leader in bispecific antibody technology, is pleased to announce a strategic collaboration with Catalent, a global Contract Development and Manufacturing Organization (CDMO) specializing in innovative drug development solutions. The collaboration will harness the combined expertise and proprietary technologies of Invenra and Catalent to co-discover novel bispecific antibody-drug conjugates. Dr. Roland Green, CEO of Invenra, remarks, “W